We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Electrical Impedance Measures Physiological Changes in Skeletal Muscle Thickness

By LabMedica International staff writers
Posted on 19 May 2011
Changes in myotube thickness were measured by measuring cellular electrical impedance.

Tracking physiological changes in skeletal muscle thickness is a direct and unbiased approach in screening therapeutic compounds that prevent skeletal muscle atrophy or induce hypertrophy. More...
In drug screening, it would be beneficial to find novel treatments that prevent muscle atrophy and other diseases associated with any morphologic change in cell shape.

Both qualitative and quantitative changes in electrical impedance as a function of cellular adhesion in real time correlated well with variation in myotube thickness caused by atrophy or hypertrophy agents. Conversely, pharmacologic blocking myotube hypertrophy prevented changes in electrical impedance.

Sergey Rakhilin PhD of Novartis (Basel, Switzerland) and colleagues used the xCELLigence system from Roche (Penzberg, Germany) to show that both qualitative and quantitative changes in electrical impedance as a function of cellular adhesion in real time correlate well with variation in myotube thickness caused by atrophy or hypertrophy agents. Conversely, pharmacologic blocking myotube hypertrophy prevented changes in electrical impedance. According to the study, impedance can be used as a reliable and sensitive biomarker for myotube atrophy or hypertrophy.

The study appeared online on April 14, 2011 in the Journal of Biomolecular Screening.

In the past, it was difficult to estimate accurate cell thickness for a couple of reasons. One is the extreme heterogeneity of the myotube cellular population and therefore the lack of a regular distribution of perturbed myotubes. Another reason is the fact that differentiated myotubes form a confluent layer, which makes it difficult to estimate parameters of individual cells. In addition, most of the atrophy or hypertrophy-induced changes in cell thickness are relatively small (less than twofold) and therefore hard to detect with low statistical error. Electrical impedance measurement overcomes these hurdles and offers a reliable method to determine cell thickness.

Related Links:
Novartis
Roche



Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Neonatal Heel Incision Device
Tenderfoot
Automatic CLIA Analyzer
Shine i6000
Urine Analyzer
respons® UDS100
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.